Royal Bank Of Canada Cuts BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $13.00

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target lowered by analysts at Royal Bank Of Canada from $14.00 to $13.00 in a report issued on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Royal Bank Of Canada’s price objective would suggest a potential upside of 37.99% from the company’s current price.

Several other research analysts have also recently weighed in on BCRX. Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. JPMorgan Chase & Co. initiated coverage on shares of BioCryst Pharmaceuticals in a research report on Monday, July 13th. They set a “neutral” rating and a $12.00 price target on the stock. Wedbush decreased their price objective on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a research report on Thursday. Wall Street Zen downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Citizens Jmp boosted their price objective on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 7th. Eight investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.60.

BioCryst Pharmaceuticals Trading Up 3.9%

BCRX traded up $0.35 during trading on Thursday, hitting $9.42. The stock had a trading volume of 1,585,365 shares, compared to its average volume of 4,986,546. BioCryst Pharmaceuticals has a 12 month low of $6.00 and a 12 month high of $11.22. The firm has a market cap of $2.39 billion, a PE ratio of -5.29 and a beta of 0.55. The company has a 50 day simple moving average of $9.32 and a 200-day simple moving average of $8.69.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The firm had revenue of $218.25 million for the quarter, compared to the consensus estimate of $183.28 million. During the same quarter in the previous year, the company earned $0.15 earnings per share. The business’s revenue was up 33.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that BioCryst Pharmaceuticals will post -2.58 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Larson Financial Group LLC boosted its position in BioCryst Pharmaceuticals by 1,188.0% during the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after buying an additional 3,267 shares during the period. Focus Partners Wealth bought a new position in BioCryst Pharmaceuticals during the third quarter worth $77,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of BioCryst Pharmaceuticals by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 2,115 shares during the period. Hilltop Holdings Inc. acquired a new stake in BioCryst Pharmaceuticals in the 1st quarter valued at $98,000. Finally, Envestnet Portfolio Solutions Inc. acquired a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter worth about $81,000. Institutional investors own 85.88% of the company’s stock.

Key Stories Impacting BioCryst Pharmaceuticals

Here are the key news stories impacting BioCryst Pharmaceuticals this week:

• Positive Sentiment: Q2 results exceeded expectations: BioCryst reported adjusted earnings of $0.30 per share, versus the $0.14–$0.15 analyst consensus, while revenue rose 33.6% year over year to $218.3 million, well above estimates of approximately $183.3 million. BioCryst Pharmaceuticals Q2 Earnings, Revenue Increase; 2026 Revenue Outlook Raised
• Positive Sentiment: Revenue outlook was raised: Management increased 2026 total revenue guidance to $690 million–$715 million, while maintaining ORLADEYO revenue guidance of $625 million–$645 million. ORLADEYO generated $158.2 million in second-quarter revenue, reinforcing the drug’s role as the company’s primary commercial growth driver. BioCryst Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Commercial and pipeline progress: BioCryst began shipping ORLADEYO oral pellets for pediatric patients on August 3 and completed enrollment in the pivotal ALPHA-ORBIT study of navenibart. These developments expand the potential patient base and provide an additional future growth opportunity. BioCryst Pharmaceuticals, Inc. 2026 Q2 Results Earnings Call Presentation
• Neutral Sentiment: Buyout speculation is unconfirmed: Retail investors have renewed acquisition speculation following the earnings beat and growing ORLADEYO sales, but no transaction or formal takeover interest was announced. BioCryst Bets on Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat
• Negative Sentiment: Profitability remains uneven: Despite reported operating profit, BioCryst continues to show a negative net margin and return on equity, and analysts still expect a full-year loss. Investors also remain dependent on continued ORLADEYO growth and successful development of navenibart.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.